Study of ALV-100 to Assess Safety, Tolerability, and PK/PD in Overweight/Obese Participants With or Without T2D

计划入组 180 人 · 首次发布于 2026 年 2 月 10 日

Sildenafil 100 mg Tablets Relative to Viagra 100 mg Tablets

计划入组 36 人 · 首次发布于 2024 年 3 月 4 日

Safety Study of CTX-100 Inhalation Solution (Formerly ETX-100)

计划入组 11 人 · 首次发布于 2009 年 10 月 12 日

ALV-002

ALV-306

ALV-304

Loyola University of Chicago

United States

Meridian Bioscience, Inc.

United States

Basilea Pharmaceutica AG

Switzerland

Alveus Doses First Patient in Phase 2 PRESERVE Trial of ALV-100 for Weight Maintenance After Semaglutide

Alveus Therapeutics Raises $160 Million Series A to Advance Novel Obesity Therapies

Alveus Therapeutics Emerges with $160M to Develop Next-Generation Obesity Therapies